세계 심장 바이오 마커 시장 : 규모 제품, 용도, 최종 용도별 예측(2023년-2032년)

Cardiac biomarkers market size is expected to record 12.8% CAGR from 2023 to 2032. The rising prevalence of cardiovascular diseases worldwide, coupled with an aging population, has spurred the need for advanced diagnostic tools. According to a new report from the World Heart Federation (WHF), nearly 20.5 million deaths happened due to cardiovascular (CVD) in 2021.

The advent of cutting-edge technologies and the growing emphasis on early detection have elevated the importance of cardiac biomarkers in clinical practice. These biomarkers, ranging from proteins to genetic markers, are becoming indispensable tools for healthcare professionals in predicting, diagnosing, and managing cardiovascular conditions, thus reshaping the landscape of cardiac care.

The cardiac biomarkers market is classified based on product, application, end-use, and region.

The natriuretic peptides segment is predicted to generate massive revenues by 2032. Natriuretic peptides, particularly B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), have become pivotal indicators for heart failure. The precision and sensitivity of these peptides in detecting cardiac stress and dysfunction have garnered widespread attention from healthcare providers. As technology advances, the development of novel natriuretic peptide assays promises enhanced diagnostic accuracy, providing clinicians with a powerful arsenal for early intervention and personalized treatment strategies.

The Congestive Heart Failure (CHF) application segment will generate high demand for cardiac biomarkers through 2032, driven by the global epidemic of heart failure. With a staggering rise in the number of CHF cases, the spectrum of CHF biomarkers, including troponins, creatine kinase-MB (CK-MB), and myoglobin, aid in the comprehensive evaluation of cardiac function. The integration of these biomarkers into routine clinical practice is reshaping the approach of managing heart failure, enabling timely interventions and improving patient outcomes.

Europe cardiac biomarkers industry is anticipated to record strong CAGR from 2023 to 2032, favored by a paradigm shift in cardiovascular care, with an increasing emphasis on preventive measures and personalized medicine. The product integration into routine clinical practice is gaining momentum, driven by collaborative efforts between healthcare institutions and innovative diagnostic companies. As the Europe region continues to embrace the latest advancements, the market is poised for sustained growth, ushering in a new era of cardiovascular healthcare across the continent.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & workings
• 1.3 Forecast calculations
• 1.4 Data Sources
  • 1.4.1 Primary
  • 1.4.2 Secondary
    • 1.4.2.1 Paid sources
    • 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Global cardiac biomarkers market 360 degree synopsis, 2018 - 2032
• 2.2 Regional trends
• 2.3 Product trends
• 2.4 Application trends
• 2.5 End-use trends

Chapter 3 Cardiac Biomarkers Industry Insights

• 3.1 COVID- 19 impact analysis
• 3.2 Industry ecosystem analysis
• 3.3 Technology landscape
• 3.4 Regulatory landscape
• 3.5 Industry impact forces
  • 3.5.1 Growth drivers
    • 3.5.1.1 Increase in prevalence of cardiovascular diseases
    • 3.5.1.2 Rise in the elderly population is leading to a higher prevalence of heart-related conditions
    • 3.5.1.3 Rising clinical research studies aimed at discovering new cardiac biomarkers
    • 3.5.1.4 Increase in point-of-care testing
  • 3.5.2 Industry pitfalls & challenges
    • 3.5.2.1 Stringent regulatory frameworks
    • 3.5.2.2 Presence and advancement in cardiac imaging technologies
• 3.6 Growth potential analysis
  • 3.6.1 By product
  • 3.6.2 By application
  • 3.6.3 By end-use
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
  • 4.1.1 Abbott Diagnostics
  • 4.1.2 Roche Diagnostics
  • 4.1.3 Siemens Healthineers
• 4.2 Competitive analysis of major market players, 2022
• 4.3 Competitive positioning matrix, 2022
• 4.4 Strategic outlook matrix, 2022

Chapter 5 Cardiac Biomarkers Market Size and Forecast, By Product, 2018-2032 (USD Million)

• 5.1 Key trends, by product
• 5.2 Troponins
• 5.3 Creatine kinase-MB (CK-MB)
• 5.4 Myoglobin
• 5.5 Natriuretic peptides
• 5.6 C-reactive protein (CRP)
• 5.7 Ischemia modified albumin
• 5.8 Other products

Chapter 6 Cardiac Biomarkers Market Size and Forecast, By Application, 2018-2032 (USD Million)

• 6.1 Key trends, by application
• 6.2 Congestive heart failure
• 6.3 Myocardial infarction
• 6.4 Acute coronary syndrome
• 6.5 Atherosclerosis
• 6.6 Other applications

Chapter 7 Cardiac Biomarkers Market Size and Forecast, By End-use, 2018-2032 (USD Million)

• 7.1 Key trends, by end-use
• 7.2 Hospital laboratory
• 7.3 Point of care testing facilities
• 7.4 Diagnostic facilities
• 7.5 Other end-users

Chapter 8 Cardiac Biomarkers Market Size and Forecast, By Region, 2018-2032 (USD Million)

• 8.1 Key trends, by region
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East & Africa

Chapter 9 Company Profiles

• 9.1 Abbott Diagnostics
• 9.2 Roche Diagnostics
• 9.3 Siemens Healthineers
• 9.4 Beckman Coulter
• 9.5 Bio-Rad Laboratories
• 9.6 Ortho Clinical Diagnostics
• 9.7 Randox Laboratories
• 9.8 Quidel Corporation
• 9.9 Radiometer
• 9.10 Tosoh Corporation
• 9.11 Meso Scale Diagnostics (MSD)
• 9.12 Thermo Fisher Scientific
• 9.13 Luminex Corporation
• 9.14 Trinity Biotech
• 9.15 Biomerieux